Table 3.
Cohort | Overall survival |
Recurrence-free survival |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
n | LCAL62 |
FOXA2 |
n | LCAL62 |
FOXA2 |
|||||
HR∗ | p | HR∗ | p | HR∗ | p | HR∗ | p | |||
TCGA | 220 | 1.2–3.1 | 0.004 | 1.0–2.5 | 0.051 | 132 | 1.03–3.7 | 0.036 | 0.7–2.4 | 0.440 |
Schabath | 374 | 1.4–3.1 | 0.0003 | 1.2–2.6 | 0.006 | 0 | NA | NA | NA | NA |
Der | 124 | 1.1–3.3 | 0.026 | 1.1–3.3 | 0.023 | 124 | 0.8–3.0 | 0.164 | 0.8–2.8 | 0.261 |
Rousseaux | 82 | 1.1–3.8 | 0.025 | 0.9–3.1 | 0.135 | 81 | 1.03–5.5 | 0.036 | 0.7–3.5 | 0.277 |
WashU | 81 | 1.1–2.9 | 0.023 | 0.9–2.2 | 0.149 | 50 | 0.8–2.5 | 0.276 | 1.1–3.6 | 0.028 |
Combined | 881 | 1.5–2.4 | 3.3E-09 | 1.3–2.0 | 1.6E-05 | 387 | 1.3–2.5 | 0.00045 | 1.03–2.0 | 0.031 |
95% confidence interval.